HuidaGene Biotechnology Co., Ltd (辉大基因) is a global clinical-stage biotechnology company focusing on the discovering, engineering, and developing CRISPR-based gene-editing tools and gene therapies to rewrite the future of genomic medicine.
Based in Shanghai and New Jersey, HuidaGene is committed to addressing patient's needs globally with various preclinical therapeutic programs covering ophthalmology, otology, myology, and neurology.
Company's CRISPR-based therapeutics offer the potential to cure patients with life-threatening conditions by repairing the cause of their disease. We are committed to transform the future of genome-editing medicine.
Company Details
- Employees
- 34
- Founded
- -
- Address
- Shanghai, Cn
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.huidagene.com
- HQ
- Shanghai
Huidagene Therapeutics Questions
Huidagene Therapeutics's website is http://www.huidagene.com
Huidagene Therapeutics's LinkedIn profile is https://www.linkedin.com/company/huidagene
Huidagene Therapeutics has
34 employees.
View email and phone details for 34
employees at Huidagene Therapeutics.
Huidagene Therapeutics's industry is
Biotechnology Research
Huidagene Therapeutics's top competitors are
Synthego,
Stylus Medicine,
American Society Of Gene & Cell Therapy,
Neurogene Inc.,
Dyne Therapeutics,
Precision Biosciences, Inc.,
Beam Therapeutics,
Atsena Therapeutics,
Yoltech Therapeutics,
Gene Editing Frontiers Llc.
Huidagene Therapeutics's categories are Biotechnology Research
Huidagene Therapeutics's founding year is 2018
